Caris Life Sciences Inc
CAI
NASDAQ
Biotechnology
$21.80
USD
-0.38 (-1.71%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.27B
Volume 3.9M
Revenue
$989.61M
TTM
— YoY
Gross Margin
70%
TTM
— YoY
Net Income
$105.14M
TTM
— YoY
Operating Cash Flow
$168.56M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 181.4 | 216.8 | 292.9 | 216.2 | 263.7 |
YoY Growth | — | — | — | — | +45.4% |
Cost of Revenue | 67.7 | 69.3 | 72.0 | 74.8 | 84.1 |
Gross Profit | 113.7 | 147.5 | 220.9 | 141.3 | 179.6 |
Selling, General & Administrative | 106.6 | 93.2 | 100.7 | 104.8 | 120.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 131.7 | 114.9 | 132.5 | 136.1 | 152.7 |
Operating Income | -18.0 | 32.6 | 88.4 | 5.3 | 26.9 |
EBITDA | -11.6 | 37.5 | 92.7 | 10.3 | 33.5 |
Other Income / Expense | -36.2 | -2.2 | -2.1 | 0.0 | -25.1 |
Total Other Income / Expense | -53.8 | -8.3 | -6.5 | -5.9 | -27.5 |
Income Before Income Taxes | -71.8 | 24.3 | 82.0 | -0.6 | -0.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 |
Net Income | -71.8 | 24.3 | 82.0 | -0.5 | -0.6 |
Consolidated Net Income / Loss | -71.8 | 24.3 | 82.0 | -0.5 | -0.6 |
Net Income Attributable to Common Shareholders | -517.2 | 24.3 | 82.0 | -0.5 | -0.6 |
Basic EPS | -$7.97 | $0.09 | $0.29 | $0.00 | $0.00 |
Diluted EPS | -$7.97 | $0.08 | $0.30 | $0.00 | $0.00 |
Basic Shares Outstanding | 64.9M | 282.1M | 286.2M | 282.6M | 282.9M |
Diluted Shares Outstanding | 64.9M | 297.2M | 271.1M | 282.6M | 282.9M |